Drug delivery device

• US 6,808,719 B2
• Filed: 07/01/2002
• Issued: 10/26/2004
• Est. Priority Date: 10/21/1999
• Status: Expired due to Term

• Current Assignee: Novartis Ag
• Original Assignee: Alcon Incorporated
• Inventors: Yaacobi, Yoseph
• Primary Examiner(s): Spear, James M.
• Application Number:
  US10/186,960
• Publication Number:
  US 20020197298A1
• Time in Patent Office: 848 Days
• Field of Search: 424/422, 424/427, 424/428, 424/423, 424/429
• US Class Current: 424/427
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

Drug delivery devices, and methods of delivering pharmaceutically active agents to a target tissue within a body using such devices, are disclosed. One drug delivery device includes a body having an internal surface for placement proximate a target tissue and a well having an opening to the internal surface. An inner core comprising a pharmaceutically active agent is disposed in the well.

Claims

1. An ophthalmic drug delivery device, comprising:

a body having;

a scleral surface having a radius of curvature that facilitates contact with a sclera of a human eye; and

a well having an opening to said scleral surface; and

a tablet disposed in said well and comprising a pharmaceutically active agent.

2. The ophthalmic drug delivery device of claim 1 wherein at least a portion of said body is made from a generally elastic material so that said generally elastic material, a geometry of said well, and a geometry of said tablet frictionally secure said tablet within said well.

3. The ophthalmic drug delivery device of claim 1 wherein said tablet is formulated to bioerode and release said pharmaceutically active agent at a controlled rate.

4. An ophthalmic drug delivery device, comprising:

a body having;

a scleral surface having a radius of curvature that facilitates contact with a sclera of a human eye;

a well having an opening to said scleral surface; and

a retaining member extending from said body proximate said opening; and

an inner core disposed in said well and comprising a pharmaceutically active agent,

whereby said retaining member helps to retain said inner core in said well.

5. The ophthalmic drug delivery device of claim 4 wherein said retaining member comprises a rim at least partially disposed around said opening.

6. An ophthalmic drug delivery device, comprising:

a body having;

a scleral surface having a radius of curvature that facilitates contact with a sclera of a human eye; and

a well having an opening to said scleral surface; and

a hydrogel disposed in said well and comprising a pharmaceutically active agent.

7. The ophthalmic drug delivery device of claim 6 wherein said hydrogel is formulated to bioerode and release said pharmaceutically active agent at a controlled rate.

8. The ophthalmic drug delivery device of claim 6 wherein said pharmaceutically active agent diffuses through said hydrogel at a controlled rate.

9. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises an anti-infective.

10. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises a steroidal anti-inflammatory agent.

11. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises a non-steroidal anti-inflammatory agent.

12. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises an anti-infective and an anti-inflammatory agent.

13. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent is for the treatment of macular degeneration.

14. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent is for the treatment of choroidial neovascularization.

15. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent is for the treatment of retinopathies.

16. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent is for the treatment of retinitis.

17. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent is for the treatment of uveitis.

18. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent is for the treatment of macular edema.

19. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent is for the treatment of glaucoma.

20. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises an angiogenesis inhibitor.

21. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises an antimetabolite.

22. An ophthalmic drug delivery device, comprising:

a body having a scleral surface for placement proximate a sclera and a well having an opening to said scleral surface; and

an inner core disposed in said well comprising a pharmaceutically active agent, wherein said pharmaceutically active agent comprises a neuroprotective drug.

23. A method of delivering a pharmaceutically active agent to the eye, said eye having a sclera, a Tenon'"'"'s capsule, and a macula, comprising the steps of:

providing a drug delivery device comprising a body having a pharmaceutically active agent disposed therein; and

disposing said device on an outer surface of said sclera and below said Tenon'"'"'s capsule.

24. The method of claim 23 wherein said drug delivery device is a tablet, and said pharmaceutically active agent is disposed in said tablet.

25. The method of claim 24 wherein said disposing step comprises disposing said tablet proximate said macula.

26. The method of claim 24 wherein said disposing step comprises disposing said tablet generally above said macula.

27. The method of claim 24 wherein said tablet is formulated to bioerode and release said pharmaceutically active agent at a controlled rate.